TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03883165

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high-intensity neck strengthening
Description: All subjects will exercise 2 days per week for 12 weeks under the direct supervision of a study-assigned strength coach with a minimum of 1 day of rest between exercise sessions.~Participants will perform a standardized set of general resistance exercises targeting the chest, shoulders, back, upper and lower extremities, and core. Additionally, they will also perform a higher number of repetitions of manual resistance neck strengthening exercises in sagittal plane flexion and extension, coronal plane lateral flexion in both directions, and axial plane rotation in both directions,as well as dumbbell shoulder shrugs.

Intervention type: OTHER
Group type: OTHER
Intervention: Control group
Description: All subjects will exercise 2 days per week for 12 weeks under the direct supervision of a study-assigned strength coach with a minimum of 1 day of rest between exercise sessions.~Participants will perform a standardized set of general resistance exercises targeting only the chest, shoulders, back, upper and lower extremities, and core, without resistance exercises specifically targeting the neck.
Study: NCT05695287

Intervention type: DRUG
Group type: OTHER
Intervention: Sevoflurane
Description: Sevoflurane
Study: NCT06339268

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive training, CogniFit App
Description: A patient will receive preoperative cognitive stimulation and physical therapy for one month before surgical treatment.
Study: NCT05152784

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Octaray catheter
Description: A high density diagnostic catheter used for substrate and activation mapping.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: VT ablation guided by substrate-mapping alone.
Study: NCT04248283

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adjustable Continence Therapy for Women (ACT)
Description: Two ACT devices are implanted in each patient. The devices are intended for implantation in the paraurethral space, with the balloons located on each side of the urethra near the bladder neck. The ports are placed subcutaneously in the labia majora. The balloons are filled after implantation with an isotonic solution via needle injection into the port. The ACT implant can be placed using local, spinal or general anesthesia with the surgical instruments (provided separately).
Study: NCT06409156

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Oblique Subcostal Transversus Abdominis Plane Block
Description: With the OSTAP block, local anesthetic is injected into the fascial plane between the posterior rectus sheath and the transversus abdominis muscle beneath the subcostal margin.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: External Oblique Intercostal Fascial Plane block
Description: With the EOIF block, local anesthetic targets the terminal part of the thoracoabdominal nerves pass behind the costal cartilage and continue anteriorly in the plane between the internal oblique and transversus abdominis muscle, before piercing the rectus abdominis sheath as anterior cutaneous branches supplying the skin of the midabdomen.
Study: NCT05254977

Intervention type: DRUG
Intervention: Standard Preparation
Description: Any kind of intervention received to reduce adverse effects

Intervention type: DRUG
Intervention: Standard Preparation
Description: Any kind of intervention received to reduce adverse effects

Intervention type: DRUG
Intervention: Standard Preparation
Description: Any kind of intervention received to reduce adverse effects

Intervention type: DRUG
Intervention: Standard Preparation
Description: Any kind of intervention received to reduce adverse effects

Intervention type: DRUG
Intervention: Standard Preparation
Description: Any kind of intervention received to reduce adverse effects

Intervention type: DRUG
Intervention: Standard Preparation
Description: Any kind of intervention received to reduce adverse effects

Intervention type: DRUG
Intervention: Standard Preparation
Description: Any kind of intervention received to reduce adverse effects

Intervention type: DRUG
Intervention: Standard Preparation
Description: Any kind of intervention received to reduce adverse effects

Intervention type: DRUG
Intervention: Standard Preparation
Description: Any kind of intervention received to reduce adverse effects

Intervention type: DRUG
Intervention: Standard Preparation
Description: Any kind of intervention received to reduce adverse effects

Intervention type: DRUG
Intervention: Standard Preparation
Description: Any kind of intervention received to reduce adverse effects

Intervention type: DRUG
Intervention: Standard Preparation
Description: Any kind of intervention received to reduce adverse effects

Intervention type: DRUG
Intervention: Standard Preparation
Description: Any kind of intervention received to reduce adverse effects

Intervention type: DRUG
Intervention: Standard Preparation
Description: Any kind of intervention received to reduce adverse effects
Study: NCT06106997

Intervention type: RADIATION
Group type: OTHER
Intervention: brain radiotherapy
Description: brain radiotherapy planned on synthetic CTs
Study: NCT05254977

Intervention type: DRUG
Intervention: Standard Preparation
Description: Any kind of intervention received to reduce adverse effects

Intervention type: DRUG
Intervention: Standard Preparation
Description: Any kind of intervention received to reduce adverse effects

Intervention type: DRUG
Intervention: Standard Preparation
Description: Any kind of intervention received to reduce adverse effects

Intervention type: DRUG
Intervention: Standard Preparation
Description: Any kind of intervention received to reduce adverse effects

Intervention type: DRUG
Intervention: Standard Preparation
Description: Any kind of intervention received to reduce adverse effects
Study: NCT06372132

Intervention type: PROCEDURE
Group type: OTHER
Intervention: G-POEM
Description: Gastric Per-Oral Endoscopic Pyloromyotomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: G-POEM
Description: Gastric Per-Oral Endoscopic Pyloromyotomy
Study: NCT05397990

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 12 weeks of moderate intensity exercise, three times a week.
Study: NCT06269445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icaritin Combined With Bevacizumab and FOLFIRI
Description: Bevacizumab and FOLFIRI are second-line treatment options for colorectal cancer; synergistic efficacy expected in combination with Icaritin
Study: NCT05558540

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: spinal cord stimulator
Description: By continuous electrical stimulation of the nerve causing endometriosis-related pain, painful inputs to the spinal cord and brain can be reduced or even eliminated. The electrical stimulation is performed by the spinal cord stimulator (SCS).
Study: NCT05579704

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Web-based wellness platform
Description: A web-based wellness platform is based on preventive self-care and contains tools to monitor nutrition, physical activity, and mental wellbeing.
Study: NCT05254977

Intervention type: DRUG
Intervention: Standard Preparation
Description: Any kind of intervention received to reduce adverse effects

Intervention type: DRUG
Intervention: Standard Preparation
Description: Any kind of intervention received to reduce adverse effects

Intervention type: DRUG
Intervention: Standard Preparation
Description: Any kind of intervention received to reduce adverse effects

Intervention type: DRUG
Intervention: Standard Preparation
Description: Any kind of intervention received to reduce adverse effects
Study: NCT05192447

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise treatment
Description: Patients selected to EG will carry out complementary cognitive and physical training under supervision of rehabilitation staff. For neuropsychological exercises, the investigators will use the RehaCom system - high quality scientific neurocognitive disorder therapy programs and software. (Time: 30 min./5 times/week per patient during RT). In this time, EG patients will do physical training (such as cycling, running on properly calibrated equipment for the circulatory system parameter measurement (1hour/ 5 days/ week), and neuromuscular and cognitive reeducation exercises using a technically advanced tool - Neuroforma computer software - 30 min/ 5 times/ week). After the end of RT, patients in EG will do a special exercise training at home under supervision of staff from the Department of Rehabilitation, and cognitive training using special tasks (3 times an hour/per week) at home, and two times/week using RehaCom and Neuroforma (60 min/sesion) in our cancer ceter.
Study: NCT05579704

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based wellness platform
Description: A web-based wellness platform is based on preventive self-care and contains tools to monitor nutrition, physical activity, and mental wellbeing.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthcare professional-facilitated online support group
Description: Participants will take part in weekly group video conferencing sessions with various health professionals (registered dietitian, mental health therapist, and exercise professional). The sessions will occur once per week for 1 hour each. The group sessions will contain cohorts of approximately 10 individuals.
Study: NCT05858424

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multidisciplinary day hospitalization
Description: This multidisciplinary day hospitalization will consist at least of a psychological interview, an interview with a social worker and a medical interview. The objectives of this medical interview, conducted by a clinician researcher, are to summarize the pathology, the treatment(s) received, and to develop a personalized after-cancer plan.~The psychological interview will assess the needs for further care, and will refer the former patient if necessary.~The social interview will take stock of the former patient's return to school and/or professional life, and direct him/her to possible applications for social assistance if needed.~If needs of supportive care emerge from the history of treatment period, some consultations can be added during the day hospitalization, like an interview with a dietician or an adapted physical activity assessment.
Study: NCT05726253

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Care + Amoxicillin
Description: Participants will be randomized to receive oral amoxicillin for a standard course (7 days)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Supportive Care + Placebo (no antibiotics)
Description: Participants will be randomized to receive oral placebo for a standard course (7 days)
Study: NCT05053490

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Static Stretching
Description: Static stretches are those in which you stand, sit or lie still and hold a single position for a period of time.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dynamic stretching
Description: Dynamic stretching involves making active movements that stretch the muscles to their full range of motion.
Study: NCT05380401

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Enfamil® DHA & ARA Supplement for Special Dietary Use
Description: Dosage: 60 mg/kg/day of DHA and 120 mg/kg/day of ARA. Route of administration: enteral tube or by oral syringe

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Enfamil® DHA & ARA Supplement for Special Dietary Use
Description: Dosage: 60 mg/kg/day of DHA and 120 mg/kg/day of ARA. Route of administration: enteral tube or by oral syringe

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Enfamil® DHA & ARA Supplement for Special Dietary Use
Description: Dosage: 60 mg/kg/day of DHA and 120 mg/kg/day of ARA. Route of administration: enteral tube or by oral syringe
Study: NCT04742699

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lemborexant (LEM) 5 mg (Z-Drug-mono cohort)
Description: 1. Pretreatment phase: Continue pre-registration treatment (Z-drug monotherapy) without LEM.~2. First treatment phase: Administer LEM 5 mg/day as a substitute for Z-Drug. Increasing LEM dose to 10 mg/day is allowed.~3. Maintenance phase: Succeed the treatment from the first treatment phase. Changing LEM dose is allowed. Rescue administration of Z-drug or RMT is allowed under a defined condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lemborexant (LEM) 5 mg (SUV-mono cohort)
Description: 1. Pretreatment phase: Continue pre-registration treatment (SUV monotherapy) without LEM.~2. First treatment phase: Administer LEM 5 mg/day as a substitute for SUV. Increasing to LEM dose to 10 mg/day is allowed.~3. Maintenance phase: Succeed the treatment of the first treatment phase. Changing LEM dose is allowed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lemborexant (LEM) 5 mg (SUV-combination cohort)
Description: 1. Pretreatment phase: Continue pre-registration treatment (SUV and BZRA combination therapy) without LEM.~2. First treatment phase: Administer LEM 5 mg/day as a substitute for SUV and continue BZRA. Increasing to LEM dose to 10 mg/day is allowed.~3. Maintenance phase: Succeed the treatment of the first treatment phase. Changing LEM dose is allowed. Decreasing dose or discontinuation of BZRA is allowed. Rescue administration of Z-drug or RMT is allowed under a defined condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lemborexant (LEM) 5 mg (RMT-combination cohort)
Description: 1. Pretreatment phase: Continue pre-registration treatment (RMT and BZRA combination therapy) without LEM.~2. First treatment phase: Administer LEM 5 mg/day as a substitute for RMT and continue BZRA. Increasing to LEM dose to 10 mg/day is allowed.~3. Maintenance phase: Succeed the treatment of the first treatment phase. Changing LEM dose is allowed. Decreasing dose or discontinuation of BZRA is allowed. Rescue administration of Z-drug or RMT is allowed under a defined condition.
Study: NCT05963659

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: nitrate-rich beetroot juice
Description: nitrate-rich beetroot juice, \~750 mg NO3- /d

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: nitrate-depleted beetroot juice
Description: nitrate-depleted beetroot juice, \~1 mg NO3- /d
Study: NCT04814797

Intervention type: OTHER
Intervention: Capnography data included in Lung Clearance Index measurement
Description: Capnography data included in Lung Clearance Index measurement (a pulmonary function test included in routinely yearly follow-up of cystic fibrosis children) will be collected and analyzed

Intervention type: OTHER
Intervention: Capnography data included in Lung Clearance Index measurement
Description: Capnography data included in Lung Clearance Index measurement (a pulmonary function test included in routinely yearly follow-up of cystic fibrosis children) will be collected and analyzed
Study: NCT05078762

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Immersive Virtual Reality
Description: Training in an iVR environment with Virtual Reality Goggles while using the bronchoscopy simulator, while the control group will train without VR goggles.
Study: NCT06396104

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobilisation with movement
Description: The physiotherapist places the medial edge of the thumb of one hand on the upper facet joint of the relevant segment, then applies superior-anterior slide to the facet joint by providing support with the thumb of the other hand. The 'gliding' movement is maintained while the patient actively performs the unilateral neck rotation movement and maintains it for a few seconds at the end of the movement. If joint movement is painful, attempts are made on the other facet joint of the same segment or on the spinous process. If this attempt does not immediately improve the patient's active joint motion, Mulligan Sustained Natural Apophyseal Glides (SNAG) will be applied to the upper part of the left zygapophysial joint, and in case of failure again, application will be made through the superior spinous process of the relevant segment. Painless joint movement will be applied in 6 repetitions and 3 sets.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham mobilisation
Description: While the patients are sitting in a chair with a supported back, the spinal segment where pain is felt in neck joint movements will be determined. Without applying a sliding movement to this segment over the facet joint, only sensory input will be given and the patient will be asked to continue the active rotation movement and wait a few seconds at the end of the movement. The application will be completed as 6 repetitions and 3 sets.
Study: NCT05700864

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cenegermin-Bkbj
Description: Cenegermin-bkbj ophthalmic solution administered as one drop in both eyes every 3 hours 4 times daily for 4 weeks
Study: NCT05686941

Intervention type: OTHER
Intervention: Trans-cutaneous Laryngeal ultrasound (TLUS)
Description: Assessment of the larynx (specifically the vocal cords) with hand held portable ultrasound device to assess the movements of the vocal cords

Intervention type: OTHER
Intervention: Trans-cutaneous Laryngeal ultrasound (TLUS)
Description: Assessment of the larynx (specifically the vocal cords) with hand held portable ultrasound device to assess the movements of the vocal cords

Intervention type: OTHER
Intervention: TLUS and simultaneous laryngoscopy
Description: Assessment of the larynx (specifically the vocal cords) with hand held portable ultrasound device to assess the movements of the vocal cords with simultaneous video laryngoscopy (usual care)
Study: NCT06407635

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Psilocybin
Description: The two psilocybin doses will be administered approximately 2 weeks apart in the form of an oral capsule. The first dose will be 25mg. For the second dosing session, participants will either remain on 25 mg of psilocybin, or will receive a dose of 40 mg, depending on the strength of subjective effects experienced during the first dosing session, as well as clinical judgment and participant preference.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: The two psilocybin doses will be administered approximately 2 weeks apart in the form of an oral capsule. The first dose will be 25mg. For the second dosing session, participants will either remain on 25 mg of psilocybin, or will receive a dose of 40 mg, depending on the strength of subjective effects experienced during the first dosing session, as well as clinical judgment and participant preference.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trauma-focused psychotherapy
Description: Components of trauma-focused psychotherapy will include Cognitive Processing Therapy and in vivo exposure. Such components of evidence-based psychotherapy may lower the safety risk profile for this vulnerable population and enhance the effect size and maintenance of psilocybin therapy.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard psychological support
Description: Standard psychological support involves providing a safe and emotionally supportive environment to participants throughout the course of their participation, and being attentive and responsive to their emotional needs. It includes continued review and discussion of experiences that participants encountered during the psilocybin sessions and the way that those experience relate to the participant's life and clinical status.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard psychological support
Description: Standard psychological support involves providing a safe and emotionally supportive environment to participants throughout the course of their participation, and being attentive and responsive to their emotional needs. It includes continued review and discussion of experiences that participants encountered during the psilocybin sessions and the way that those experience relate to the participant's life and clinical status.
Study: NCT05582928

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neurofeedback
Description: Neurofeedback training during which participant will be asked to change the size of a bar using different strategies to vary the parameters of its current brain's states (neurofeedback training) computed on the realtime EEG signals.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neurofeedback
Description: Neurofeedback training during which participant will be asked to change the size of a bar using different strategies to vary the parameters of its current brain's states (neurofeedback training) computed on the realtime EEG signals.
Study: NCT06087861

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiotherapy
Description: Radiation will be delivered by external beam techniques to the tumor and areas of possible microscopic disease at a dose of 30 Gy divided into 5 equal fractions of 6 Gy (administered over a total of 5 to 10 business day
Study: NCT05507112

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 inhibitor
Description: Tislelizumab (3 cycles): 200mg i.v. q3w on day 1 of each cycle, and starting from the second week after the start of radiotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine 1650mg/m2/d orally twice-daily, 5 days a week for a total of 5 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine 1650mg/m2/d orally twice-daily, 5 days a week for a total of 5 weeks.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Long-course radiation therapy
Description: 45-50 Gy/day, 5 days a week for a total of 5 weeks.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Long-course radiation therapy
Description: 45-50 Gy/day, 5 days a week for a total of 5 weeks.
Study: NCT06175949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-7085 Tablets
Description: HRS-7085 Tablets, PO, 2mg、5mg、8mg、10mg、12mg、15mg, QD,

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HRS-7085 simulant
Description: PO, 2mg、5mg、8mg、10mg、12mg、15mg, QD
Study: NCT05072808

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: View PACCI-ED and referral recommendations
Description: Results of parent completed PACCI-ED and referral recommendations
Study: NCT05950386

Intervention type: OTHER
Intervention: Lead exposure
Description: The lead-acid battery factory workers will exposure to lead via Inhalation of lead particles, ingestion of lead-contaminated dust and water.
Study: NCT00900588

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: split-virion pandemic influenza vaccine (H5N1 strain NIBRG-14)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: split-virion pandemic influenza vaccine (H5N1 strain NIBRG-14)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: split-virion pandemic influenza vaccine (H5N1 strain NIBRG-14)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: split-virion pandemic influenza vaccine (H5N1 strain NIBRG-14)